Study to Evaluate the Efficacy and Safety of Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer
Latest Information Update: 20 Dec 2024
At a glance
- Drugs Dalpiciclib (Primary) ; Famitinib (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 17 Dec 2024 Status changed from active, no longer recruiting to discontinued.
- 03 May 2023 Status changed from recruiting to active, no longer recruiting.
- 25 Jan 2022 Status changed from not yet recruiting to recruiting.